Abstract
Background: The medication-related osteonecrosis of the jaws is an uncommon severe complication following utilization of certain drugs, but its occurrence has great impact on the patient’s quality of life. Various treatment modalities are used to manage the lesions, including conservative and surgical procedures. Ozone (O3) therapy emerges as an alternative of non-invasive therapy that can benefit the affected patient without surgical risks, due to the potential of stimulate the activation and migration of fibroblasts in an injured area. Case presentation: This article reports the conservative treatment of a maxillary stage 3 medication-related osteonecrosis, in a partial edentulous patient previously treated with intravenous bisphosphonate for multiple myeloma, who had previous cardiac illness. Conclusion: The stage 3 medication-related osteonecrosis was successfully treated with ozone (O3) gas injection and irrigation with ozonated water, with full coverage of the bone and no suppuration or pain at the end of the treatment. No recurrence was seen after twelve months of follow-up.
Highlights
IntroductionMedication-related osteonecrosis of the jaws (MRONJ), previously known as bisphosphonate-related osteonecrosis of the jaws, has changed its nomenclature since it is known that both antiresorptive and anti-angiogenic medications have potential to develop this complication (Ruggiero et al, 2014; Blus, Giannelli, Szmukler-Moncler & Orru, 2017)
Ozone (O3) therapy emerges as an alternative of non-invasive therapy that can benefit the affected patient without surgical risks, due to the potential of stimulate the activation and migration of fibroblasts in an injured area
Case presentation: This article reports the conservative treatment of a maxillary stage 3 medicationrelated osteonecrosis, in a partial edentulous patient previously treated with intravenous bisphosphonate for multiple myeloma, who had previous cardiac illness
Summary
Medication-related osteonecrosis of the jaws (MRONJ), previously known as bisphosphonate-related osteonecrosis of the jaws, has changed its nomenclature since it is known that both antiresorptive and anti-angiogenic medications have potential to develop this complication (Ruggiero et al, 2014; Blus, Giannelli, Szmukler-Moncler & Orru, 2017) The diagnosis of this lesion is defined based on the presence of a non-healing bone exposure area in the jaws for more than 8 weeks of observation, in a patient with current or previous history of antiresorptive or angiogenic therapy, with intra or extra-oral fistula and no history of radiotherapy on the jaw or metastatic disease on the area (Ruggiero et al, 2014).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
